Immunovant, Inc.
NASDAQ:IMVT · NASDAQ Global Select
+$0.69 today
Vol 3.20M · Avg 1.84M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-59.3%
avg 976.1%
ROIC
-62.5%
avg 976.5%
ROA
-52.8%
avg -13460.1%
Analysis
ROA is currently the strongest return metric at -52.8% versus its period average of -13460.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Tiago Girao | Chief Financial Officer | $871,065.00 | — | 47 | $247,596.00 | 0.12% |
Jay S. Stout | Chief Technology Officer | $683,490.00 | — | 62 | $251,685.00 | 0.12% |
Melanie Gloria | Chief Operating Officer | $575,913.00 | — | 48 | $244,973.00 | 0.12% |
Christopher Van Tuyl | Chief Legal Officer & Corporate Secretary | $549,038.00 | — | 50 | $183,231.00 | 0.09% |
Frank Torti | Executive Chairperson of the Board | $92,500.00 | — | 47 | $1.01M | 0.49% |
Eric Venker | Chief Executive Officer & Director | $55,000.00 | — | 39 | $336,043.00 | 0.16% |
Andy Deig | Senior Vice President of Strategic Finance | — | — | — | — | — |
Becky Merlina | Senior VP & Global Head of Quality | — | — | — | — | — |
Christine Blodgett | Senior Vice President of Human Resources | — | — | — | — | — |
Julie Kirschling | Senior Vice President of Program & Alliance Management | — | — | — | — | — |
Sheetal Patel | Senior Vice President of Clinical Development | — | — | — | — | — |
Yan Zheng | Senior Vice President of Biostatistics, Programming & Data Management | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$350.00M
Sells
39
$11.62M
Net Sentiment
+$338.38M
Net buying
Most Active
Stout Jay S
10 transactions
1–10 of 40
Analysis
Insiders reported 1 buys worth $350.00M and 39 sells worth $11.62M over the last 12 months. That adds up to net buying of $338.38M. Stout Jay S was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.49B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.99B
Akero Therapeutics, Inc.
AKRO
$4.50B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.83B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.70B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.63B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.62B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.30B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.77B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Who manages IMVT?
Immunovant, Inc. (IMVT) lists 12 active executives. The top listed executive is Melanie Gloria, Chief Operating Officer.
Are IMVT insiders buying or selling?
Recent insider activity shows net buying of $754.41M.
Explore More
Continue the stock analysis
Jump to another research area for this company.